TGFBR1 and cancer: Typically, compared with patients with a low TGFβ-ALK5 signature, cancer patients with an increased TGFβ-ALK5 signature exhibit a noticeable decrease in responsiveness to immune checkpoint inhibitors due to immune evasion and immune exclusion [21, 22].